Lipocine (NASDAQ:LPCN) Announces Quarterly Earnings Results

Lipocine (NASDAQ:LPCN) posted its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.31, Zacks reports. Lipocine had a negative net margin of 755.39% and a negative return on equity of 64.75%. The firm had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $0.16 million.

Lipocine Price Performance

Shares of NASDAQ LPCN traded up $0.04 during mid-day trading on Friday, hitting $1.57. The company had a trading volume of 507,960 shares, compared to its average volume of 702,409. The stock has a market cap of $12.94 million, a price-to-earnings ratio of -0.88 and a beta of 0.49. Lipocine has a 12 month low of $1.36 and a 12 month high of $12.37. The firm’s 50 day simple moving average is $1.93 and its two-hundred day simple moving average is $3.81.

Wall Street Analyst Weigh In

A number of research analysts have commented on LPCN shares. HC Wainwright reaffirmed a “neutral” rating and set a $4.00 target price on shares of Lipocine in a report on Monday, September 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Lipocine in a research report on Tuesday, September 22nd. Wall Street Zen upgraded Lipocine from a “sell” rating to a “hold” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings raised shares of Lipocine from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 29th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Lipocine presently has a consensus rating of “Hold” and an average price target of $4.00.

Insider Transactions at Lipocine

In related news, Director John Higuchi acquired 15,970 shares of the stock in a transaction that occurred on Wednesday, September 30th. The stock was purchased at an average cost of $2.23 per share, for a total transaction of $35,613.10. Following the purchase, the director directly owned 241,365 shares in the company, valued at $538,243.95. This represents a 7.09% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders purchased 37,568 shares of company stock worth $82,174. Insiders own 4.69% of the company’s stock.

Lipocine Company Profile

Lipocine Inc is a biopharmaceutical company focused on developing oral therapies for conditions with significant unmet medical needs. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and clinical performance of active pharmaceutical ingredients that may otherwise have limited effectiveness when taken orally.

Lipocine’s lead product is Tlando, an oral testosterone replacement therapy containing testosterone undecanoate. The U.S. Food and Drug Administration approved Tlando in 2022 for testosterone replacement therapy in adult males with hypogonadism associated with an underlying medical condition.